DBH抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Mouse liver tissue, Primary antibody: P08217(DBH Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P08217(DBH Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

**Background of DBH Antibodies**

Dopamine β-hydroxylase (DBH) is a critical enzyme in the catecholamine biosynthesis pathway, catalyzing the conversion of dopamine to norepinephrine. Primarily located in the adrenal medulla and sympathetic nerve terminals, DBH is essential for maintaining sympathetic nervous system function and regulating cardiovascular, metabolic, and stress responses. DBH antibodies target this enzyme and are widely used in research and diagnostics to study catecholaminergic systems.

DBH dysfunction has been implicated in cardiovascular disorders (e.g., hypertension), neurodegenerative diseases (e.g., Parkinson’s), and psychiatric conditions (e.g., schizophrenia). Antibodies against DBH enable the detection of enzyme levels in tissues or bodily fluids, aiding in the diagnosis of neuroendocrine tumors like pheochromocytoma or paraganglioma. They also serve as tools to explore DBH’s role in autonomic dysfunction or genetic variations affecting enzyme activity.

In research, DBH antibodies are employed in techniques such as ELISA, immunohistochemistry, and Western blotting to map catecholaminergic pathways, assess DBH expression in disease models, or validate gene-editing outcomes. Notably, reduced DBH activity, linked to specific polymorphisms, is associated with cognitive and behavioral traits, highlighting its broader physiological relevance.

Overall, DBH antibodies are pivotal in elucidating the enzyme’s biological and pathological roles, bridging insights into neurotransmission, disease mechanisms, and therapeutic targeting.